Neurotensin: An endogenous antipsychotic? Commentary

Becky Kinkead; Charles B. Nemeroff

doi:10.1016/S1471-4892(01)00128-X

Neurotensin: An endogenous antipsychotic? Commentary

Becky Kinkead, Charles B. Nemeroff

Research output: Contribution to journal › Comment/debate › peer-review

51 Scopus citations

Abstract

Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.

Original language	English (US)
Pages (from-to)	99-103
Number of pages	5
Journal	Current Opinion in Pharmacology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1016/S1471-4892(01)00128-X
State	Published - Feb 1 2002
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1016/S1471-4892(01)00128-X

Fingerprint Dive into the research topics of 'Neurotensin: An endogenous antipsychotic? Commentary'. Together they form a unique fingerprint.

Cite this

@article{41a85cd7288342bab01e97cb2101baab,

title = "Neurotensin: An endogenous antipsychotic? Commentary",

abstract = "Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.",

author = "Becky Kinkead and Nemeroff, {Charles B.}",

year = "2002",

month = feb,

day = "1",

doi = "10.1016/S1471-4892(01)00128-X",

language = "English (US)",

volume = "2",

pages = "99--103",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Neurotensin

T2 - An endogenous antipsychotic? Commentary

AU - Kinkead, Becky

AU - Nemeroff, Charles B.

PY - 2002/2/1

Y1 - 2002/2/1

N2 - Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.

AB - Despite evidence from a variety of experimental approaches implicating the neuropeptide neurotensin in both the mechanism of action of antipsychotic drugs and the pathophysiology of schizophrenia, there has been some debate as to whether a peripherally administered neurotensin receptor agonist represents a sound strategy for the development of a novel class of antipsychotic drugs.

UR - http://www.scopus.com/inward/record.url?scp=0036467316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036467316&partnerID=8YFLogxK

U2 - 10.1016/S1471-4892(01)00128-X

DO - 10.1016/S1471-4892(01)00128-X

M3 - Comment/debate

C2 - 11786316

AN - SCOPUS:0036467316

VL - 2

SP - 99

EP - 103

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

IS - 1

ER -